Vera Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Vera Therapeutics, Inc. (VERA) reported Debt Securities, Available-for-sale, Unrealized Loss of $224.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2023-03-28
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-12-31 was -$55.00K.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-09-30 was $127.00K.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-06-30 was $140.00K.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-03-31 was $12.00K.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2022 was $224.00K.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2021 was $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $72.00K derived: sum of 2 quarters · filed 2023-03-28 | $212.00K derived: sum of 3 quarters · filed 2023-03-28 | $224.00K 10-K · filed 2023-03-28 |
| 2022-09-30 | $127.00K 10-Q · filed 2022-11-09 | $267.00K derived: sum of 2 quarters · filed 2022-11-09 | $279.00K 10-Q · filed 2022-11-09 | $279.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2022-06-30 | $140.00K 10-Q · filed 2022-08-10 | $152.00K 10-Q · filed 2022-08-10 | $152.00K derived: sum of 3 quarters · filed 2023-03-28 | $152.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2022-03-31 | $12.00K 10-Q · filed 2022-05-16 | $12.00K derived: sum of 2 quarters · filed 2023-03-28 | $12.00K derived: sum of 3 quarters · filed 2023-03-28 | $12.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 derived: sum of 3 quarters · filed 2023-03-28 | $0.00 10-K · filed 2023-03-28 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |